Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Small‐molecule glucokinase activators (GKAs) are currently being investigated as therapeutic options for the treatment of type 2 diabetes (T2D). Because liver overexpression of glucokinase is thought to be associated with altered lipid profiles, this study aimed at assessing the potential lipogenic risks linked to oral GKA administration. Experimental Approach: Nine GKA candidates were qualified for their ability to activate recombinant glucokinase and to stimulate glycogen synthesis in rat hepatocytes and insulin secretion in rat INS‐1E cells. In vivo activity was monitored by plasma glucose and HbA1c measurements after oral administration in rodents. Risk‐associated effects were assessed by measuring hepatic and plasma triglycerides and free fatty acids, as well as plasma aminotransferases, and alkaline phosphatase. Key Results: GKAs, while efficiently decreasing glycaemia in acute conditions and HbA1c levels after chronic administration in hyperglycemic db/db mice, were potent inducers of hepatic steatosis. This adverse outcome appeared as soon as 4 days after daily oral administration at pharmacological doses and was not transient. GKA treatment similarly increased hepatic triglycerides in diabetic and normoglycaemic rats, together with a pattern of metabolic phenotypes including different combinations of increased plasma triglycerides, free fatty acids, alanine and aspartyl aminotransferases, and alkaline phosphatase. GKAs belonging to three distinct structural families induced hepatic steatosis in db/db mice, arguing in favour of a target‐mediated, rather than a chemical class‐mediated, effect. Conclusion and Implications: Given the risks associated with fatty liver disease in the general population and furthermore in patients with T2D, these findings represent a serious warning for the use of GKAs in humans. Linked Article: This article is commented on by Rees and Gloyn, pp. 335–338 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476‐5381.2012.02201.x
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
Saxena, R., Voight, B. F., Lyssenko, V., Burtt, N. P., de Bakker, P. I. W., Chen, H., Roix, J. J., Kathiresan, S., Hirschhorn, J. N., Daly, M. J., et al. (2007) · Science · doi:10.1126/science.1142358 · Cited by 2,843 · cited 1×
“More recently, genomewide scan studies revealed that single nucleotide polymorphisms in GCKR, a liver-specific GK inhibitory protein, were associated with T2D or plasma TG levels (Saxena et al., 2007; Santoro et al., 2012).”
BackgroundHuman Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089 · cited 1×
“Furthermore, longer-term treatment may rapidly progress from relatively benign hepatic steatosis to steatohepatitis, in turn cirrhosis, and ultimately progress to hepatocellular carcinoma (Cohen et al., 2011).”
BackgroundGuidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592 · cited 1×
“Animals and in vivo studies All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny et al., 2010; McGrath et al., 2010).”
BackgroundNewly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585 · cited 1×
“The phenotype of this SNP was characterized by plasma hypertriglyceridaemia and fatty liver in humans (Willer et al., 2008; Beer et al., 2009; Santoro et al., 2012), strikingly similar to the effect observed with GKAs in the present study.”
ResultLipid-induced insulin resistance: unravelling the mechanism
Samuel, V. T., Petersen, K. F., & Shulman, G. I. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60408-4 · Cited by 1,189
Type 2 diabetes across generations: from pathophysiology to prevention and management
Nolan, C. J., Damm, P., & Prentki, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60614-4 · Cited by 923 · cited 1×
“It is often associated with various disorders such as altered lipid metabolism, heart disease, vascular complications and muti-organ failure (Nolan et al., 2011).”
BackgroundBeer, N. L., Tribble, N. D., McCulloch, L. J., Roos, C., Johnson, P. R. V., Orho-Melander, M., & Gloyn, A. L. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp357 · Cited by 401 · cited 2×
“The phenotype of this SNP was characterized by plasma hypertriglyceridaemia and fatty liver in humans (Willer et al., 2008; Beer et al., 2009; Santoro et al., 2012), strikingly similar to the effect observed with GKAs in the present study.”
BackgroundResult
Cited by
Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?
Valenti, L., Bugianesi, E., Pajvani, U., & Targher, G. (2016) · Liver International · doi:10.1111/liv.13185 · Cited by 171
Glucokinase regulatory protein: complexity at the crossroads of triglyceride and glucose metabolism
Raimondo, A., Rees, M. G., & Gloyn, A. L. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000155 · Cited by 118
“Data suggest that increased hepatic GCK activity due to loss of GKRP function has negative long-term effects on whole-animal glucose and lipid homeostasis, particularly in the context of high fat and high sugar diets [47,61].”
BackgroundA comprehensive map of human glucokinase variant activity
Gersing, S., Cagiada, M., Gebbia, M., Gjesing, A. P., Coté, A. G., Seesankar, G., Li, R., Tabet, D., Weile, J., Stein, A., et al. (2023) · Genome Biology · doi:10.1186/s13059-023-02935-8 · Cited by 55
Insulin Regulation of Hepatic Lipid Homeostasis
Uehara, K., Santoleri, D., Whitlock, A. E. G., & Titchenell, P. M. (2023) · Comprehensive Physiology · doi:10.1002/cphy.c220015 · Cited by 49
Franco, L. F., Szarf, G., Dotto, R. P., Dib, S. A., Moises, R. S., Giuffrida, F. M. A., & Reis, A. F. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108867 · Cited by 9
Metadata
- Authors
- De Ceuninck, F., Kargar, C., Ilic, C., Caliez, A., Rolin, J., Umbdenstock, T., Vinson, C., Combettes, M., de Fanti, B., Harley, E., Sadlo, M., Lefèvre, A., Broux, O., Wierzbicki, M., Fourquez, J., Perron‐Sierra, F., Kotschy, A., & Ktorza, A.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-12-20
- Volume
- 168
- Issue
- 2
- Pages
- 339-353
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1602648506
- Cited by
- 74
- References
- 8
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.